Cover Image
市場調查報告書

Tonix Pharmaceuticals Holding Corp.的產品平台分析

Tonix Pharmaceuticals Holding Corp. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 321355
出版日期 內容資訊 英文 32 Pages
訂單完成後即時交付
價格
Back to Top
Tonix Pharmaceuticals Holding Corp.的產品平台分析 Tonix Pharmaceuticals Holding Corp. - Product Pipeline Review - 2015
出版日期: 2015年05月27日 內容資訊: 英文 32 Pages
簡介

Tonix Pharmaceuticals Holding Corp.是進行中樞神經系統疾病治療藥的開發的製藥企業。

本報告提供Tonix Pharmaceuticals Holding Corp. 的治療藥開發平台的現狀及各開發階段比較分析、藥物標的、作用機制、給藥途徑、各分子類型的治療藥的評估、最新的開發平台趨勢和中止的計劃相關資訊等。

Tonix Pharmaceuticals Holding Corp.的基本資料

Tonix Pharmaceuticals Holding Corp.概要

  • 主要資訊
  • 企業資料

Tonix Pharmaceuticals Holding Corp.:R&D概要

  • 主要的治療範圍

Tonix Pharmaceuticals Holding Corp.:開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品
  • 聯合治療模式

Tonix Pharmaceuticals Holding Corp.:開發中產品概況

  • 後期開發中產品
    • 第三階段的產品/聯合治療模式
  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 在前臨床階段的產品/聯合治療模式

Tonix Pharmaceuticals Holding Corp.:藥物簡介

  • TNX-102
  • TNX-201
  • (disulfiram + selegiline)
  • 輻射中毒及化學毒性的小分子
  • 天花疫苗

Tonix Pharmaceuticals Holding Corp.:開發平台分析

  • 各標的
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Tonix Pharmaceuticals Holding Corp.:最近的開發平台趨勢

Tonix Pharmaceuticals Holding Corp.:暫停中的計劃

Tonix Pharmaceuticals Holding Corp.:總公司和子公司的所在地

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07123CDB

Summary

Global Markets Direct's, 'Tonix Pharmaceuticals Holding Corp. - Product Pipeline Review - 2015', provides an overview of the Tonix Pharmaceuticals Holding Corp.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Tonix Pharmaceuticals Holding Corp.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Tonix Pharmaceuticals Holding Corp. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Tonix Pharmaceuticals Holding Corp.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Tonix Pharmaceuticals Holding Corp.'s pipeline products

Reasons to buy

  • Evaluate Tonix Pharmaceuticals Holding Corp.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Tonix Pharmaceuticals Holding Corp. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Tonix Pharmaceuticals Holding Corp.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Tonix Pharmaceuticals Holding Corp. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Tonix Pharmaceuticals Holding Corp.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Tonix Pharmaceuticals Holding Corp. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Tonix Pharmaceuticals Holding Corp. Snapshot
    • Tonix Pharmaceuticals Holding Corp. Overview
    • Key Information
    • Key Facts
  • Tonix Pharmaceuticals Holding Corp. - Research and Development Overview
    • Key Therapeutic Areas
  • Tonix Pharmaceuticals Holding Corp. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Combination Treatment Modalities
  • Tonix Pharmaceuticals Holding Corp. - Pipeline Products Glance
    • Tonix Pharmaceuticals Holding Corp. - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • Tonix Pharmaceuticals Holding Corp. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
    • Tonix Pharmaceuticals Holding Corp. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Tonix Pharmaceuticals Holding Corp. - Drug Profiles
    • TNX-102
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TNX-201
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • (disulfiram + selegiline)
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Radiation and Chemical Toxicity
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • small pox vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Tonix Pharmaceuticals Holding Corp. - Pipeline Analysis
    • Tonix Pharmaceuticals Holding Corp. - Pipeline Products by Target
    • Tonix Pharmaceuticals Holding Corp. - Pipeline Products by Route of Administration
    • Tonix Pharmaceuticals Holding Corp. - Pipeline Products by Molecule Type
    • Tonix Pharmaceuticals Holding Corp. - Pipeline Products by Mechanism of Action
  • Tonix Pharmaceuticals Holding Corp. - Recent Pipeline Updates
  • Tonix Pharmaceuticals Holding Corp. - Dormant Projects
  • Tonix Pharmaceuticals Holding Corp. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Tonix Pharmaceuticals Holding Corp., Key Information
  • Tonix Pharmaceuticals Holding Corp., Key Facts
  • Tonix Pharmaceuticals Holding Corp. - Pipeline by Indication, 2015
  • Tonix Pharmaceuticals Holding Corp. - Pipeline by Stage of Development, 2015
  • Tonix Pharmaceuticals Holding Corp. - Monotherapy Products in Pipeline, 2015
  • Tonix Pharmaceuticals Holding Corp. - Combination Treatment Modalities in Pipeline, 2015
  • Tonix Pharmaceuticals Holding Corp. - Phase III, 2015
  • Tonix Pharmaceuticals Holding Corp. - Phase II, 2015
  • Tonix Pharmaceuticals Holding Corp. - Preclinical, 2015
  • Tonix Pharmaceuticals Holding Corp. - Pipeline by Target, 2015
  • Tonix Pharmaceuticals Holding Corp. - Pipeline by Route of Administration, 2015
  • Tonix Pharmaceuticals Holding Corp. - Pipeline by Molecule Type, 2015
  • Tonix Pharmaceuticals Holding Corp. - Pipeline Products by Mechanism of Action, 2015
  • Tonix Pharmaceuticals Holding Corp. - Recent Pipeline Updates, 2015
  • Tonix Pharmaceuticals Holding Corp. - Dormant Developmental Projects,2015

List of Figures

  • Tonix Pharmaceuticals Holding Corp. - Pipeline by Top 10 Indication, 2015
  • Tonix Pharmaceuticals Holding Corp. - Pipeline by Stage of Development, 2015
  • Tonix Pharmaceuticals Holding Corp. - Monotherapy Products in Pipeline, 2015
  • Tonix Pharmaceuticals Holding Corp. - Pipeline by Top 10 Target, 2015
  • Tonix Pharmaceuticals Holding Corp. - Pipeline by Top 10 Route of Administration, 2015
  • Tonix Pharmaceuticals Holding Corp. - Pipeline by Top 10 Molecule Type, 2015
  • Tonix Pharmaceuticals Holding Corp. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top